Comparison of thrice daily biphasic human insulin (30/70) versus basal detemir & bolus aspart in patients with poorly controlled type 2 diabetes mellitus - A pilot study

Indian Journal of Medical Research

Volumn 135, Issue 1, 2012, Pages 78-83

  Shanmugasundar, G ^a   Bhansali, Anil ^a   Walia, Rama ^a   Dutta, Pinaki ^a   Upreti, Vimal ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Biphasic human insulin 30:70; Insulin analogues; T2DM

Indexed keywords

BIPHASIC HUMAN INSULIN; BIPHASIC INSULIN; GLUCOSE; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN ASPART; INSULIN DETEMIR; METFORMIN; PIOGLITAZONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BEDTIME DOSAGE; BLOOD GLUCOSE MONITORING; BODY FAT; BODY HEIGHT; BODY MASS; BODY WEIGHT; BOLUS INJECTION; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DISEASE CONTROL; DISEASE DURATION; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INSULIN SENSITIVITY; KIDNEY FUNCTION TEST; LIFESTYLE MODIFICATION; LIVER FUNCTION TEST; MALE; MEAL; NON INSULIN DEPENDENT DIABETES MELLITUS; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; WAIST CIRCUMFERENCE; WEIGHT GAIN;

ADULT; BIPHASIC INSULINS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN ASPART; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; PILOT PROJECTS; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 84857803275     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: 10.4103/0971-5916.93428     Document Type: Article

References (14)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
2. UKPDS Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
3. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2010; 33 (Suppl 1): S11-S61.
4. Coates PA, Ollerton RL, Luzio SD, Ismail I, Owens DR. A glimpse of the"natural history" of established type 2 (noninsulin dependent) diabetes mellitus from the spectrum of metabolic and hormonal responses to a mixed meal at the time of diagnosis. Diabetes Res Clin Pract 1994; 26: 177-187.
5. U.K. Prospective Diabetes Study Group. U.K. prospective diabetes study 16: overview of six years' therapy of type 2 diabetes: a progressive disease. Diabetes 1995; 44: 1249-1258.
6. Ligthelm RJ, Mouritzen U, Lynggaard H, Landin-Olsson M, Fox C, le Devehat C. Biphasic insulin aspart given thrice daily is as efficacious as a basal-bolus insulin regimen with four daily injections. Exp Clin Endocrinol Diabetes 2006; 114: 511-519.
7. American Diabetes Association workgroup on hypoglycaemia. Defining and reporting hypoglycaemia in diabetes. Diabetes care 2005; 5: 1245-1312.
8. Garber AJ, Wahlen J, Wahl T, Bressler P, Braceras R, Allen E, et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes Obes Metab 2006; 8: 58-66.
9. Holman RR, Farmer A, Davies MJ, Levy JC, Darbyshire LJ, Keenan JF, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009; 361: 1736-1747.
10. Clements MR, Tits J, Kinsley BJ. Improved glycaemic control of thrice-daily biphasic insulin aspart compared with twicedaily biphasic human insulin. Diabetes Obes Metab 2008; 10: 229-237.
11. Ross EM. Pharmacodynamics: mechanisms of drug action and the relationship between drug concentration and effect. In: Hardman JG, Gilman AG, Limbird LE, editors. Goodman and Gillman's: the pharmacological basis of therapeutics, 9th ed. New York: McGraw-Hill; 1996. p. 29-41.
12. Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 2004; 47: 622-629.
13. Chapman TM, Perry CM. Insulin detemir: A review of its use in the management of type 1 and 2 diabetes mellitus. Drugs 2004; 64: 2577-2595.
14. Oiknine R, Bernbaum M, Mooradian AD. A critical appraisal of the role of insulin analogues in the management of diabetes mellitus. Drugs 2005; 65: 325-340.